When it comes to food-related deaths in the United States, peanut allergy is the leading cause. Unfortunately, it is also one of the most common allergies in the country, and children are at a higher risk.
Many schools and child care centers have banned products that contain any traces of peanuts. Some food manufactures even tweaked their recipes so they can be nut-free, and those that aren’t able to do so added warning labels to their packaging.
For decades, researchers have been carrying out studies in hopes that they could come up with a cure or treatment plan that can help those who are currently suffering from the allergy and even prevent future cases.
Last year, experts found that if a child is introduced to peanuts starting at four months old, there’s a “moderate certainty” that the risk of developing a peanut allergy can be reduced. This conclusion was reached after looking at the results of more than 140 studies.
Now, a pharmaceutical company called Aimmune Therapeutics has been given the green light to develop a new treatment drug that could finally end the peanut allergy epidemic.
The U.S. company’s clinical trial has passed the FDA requirements after the results of its late-stage clinical study proved that their product is effective. Aimmune is now preparing to file for approval of their drug in the U.S. by the end of 2018.
Of course, we’re all curious about how this new treatment will work, and luckily, Aimmune has made the details of the drug public.